|Publisher||Centre for Reviews and Dissemination/ Centre for Health Economics|
|Publication status||Published - 2010|
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.
CRD and CHE Technology Assessment Group, Mark Rodgers, Marta O Soares, D. Epstein, Huiqin Yang, Alison Jane Eastwood
Research output: Book/Report › Other report